Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. boosted its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 14.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 10,360 shares of the company’s stock after acquiring an additional 1,275 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Enliven Therapeutics were worth $233,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new stake in shares of Enliven Therapeutics during the third quarter worth about $256,000. Verition Fund Management LLC acquired a new stake in Enliven Therapeutics in the 3rd quarter worth about $271,000. The Manufacturers Life Insurance Company purchased a new stake in Enliven Therapeutics during the 2nd quarter worth approximately $322,000. Franklin Resources Inc. acquired a new position in shares of Enliven Therapeutics during the third quarter valued at approximately $559,000. Finally, Quest Partners LLC lifted its position in shares of Enliven Therapeutics by 1,226.4% in the third quarter. Quest Partners LLC now owns 21,117 shares of the company’s stock valued at $539,000 after acquiring an additional 19,525 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock opened at $21.86 on Monday. Enliven Therapeutics, Inc. has a 1 year low of $10.90 and a 1 year high of $30.03. The company’s 50 day simple moving average is $23.04 and its 200-day simple moving average is $24.27. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -11.51 and a beta of 1.04.

Insider Activity at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock in a transaction on Friday, December 27th. The stock was sold at an average price of $22.15, for a total value of $74,202.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Anish Patel sold 21,700 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $24.18, for a total value of $524,706.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 35,450 shares of company stock worth $845,048. 29.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Robert W. Baird increased their target price on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. BTIG Research assumed coverage on Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 target price for the company. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $38.25.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.